Ascentage Pharma Presents Preclinical Cancer Drug Data
Analysis based on 7 articles · First reported Mar 18, 2026 · Last updated Mar 18, 2026
The presentation of positive preclinical data for Ascentage Pharma's drug candidates at a major cancer research meeting could lead to increased investor confidence and potentially a positive movement in Ascentage Pharma's stock price. This event highlights the ongoing innovation in the biotechnology sector, particularly in cancer therapies.
Ascentage Pharma Group International announced that four abstracts detailing the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2026, scheduled for April 17-22, 2026, in San Diego, CA, USA. The presented data will cover three of the company's novel drug candidates: Olverembatinib (HQP1351), a BCR-ABL tyrosine kinase inhibitor; APG-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor; and APG-5918, a PRC2/EED inhibitor. The abstracts highlight Olverembatinib's efficacy in endometrial carcinoma and mantle cell lymphoma models, APG-2449's ability to enhance antitumor activity in BRAF V600E-mutant tumor models, and APG-5918's synergy with topoisomerase I inhibitors in small-cell lung cancer models. These drug candidates are currently under investigation and have not yet received approval from the United States===Food and Drug Administration.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard